News

February 11, 2019 In Events

InCarda at BIO CEO & Investor Conference

February 11, 2019 - New York, NY At the BIO CEO and Investor Conference, Dr. Grace Colón was a panelist for a discussion on “Attacking Biological Mechanisms of Aging to Extend Healthspan” where she discussed a range of topics including the correlated risks of aging to...

January 30, 2019 In Press Releases

New Patent Issuances Strengthen InCarda Therapeutics’ Intellectual Property Portfolio Covering Novel Inhaled Cardiovascular Therapies

U.S. Patent Broadly Expands Coverage for Inhaled Treatment of Cardiovascular Disease to Include all Class I – IV Antiarrhythmic Drugs Additional U.S. Patent Provides Coverage for Combination of Arrhythmia Electronic Monitoring with Treatment Initiation; Supports Vision of Empowering Patients to Rapidly Detect and Arrest Atrial Fibrillation...

January 24, 2019 In Events

InCarda at AF Symposium

January 24, 2019 - Boston, MA At the 2019 AF Symposium held in Boston, MA, Dr. Jeremy Ruskin presented an overview InCarda’s program of inhaled flecainide for treatment of Paroxysmal Atrial Fibrillation to several hundred clinicians in the audience.  Dr. Ruskin is Founder and Director of...

January 8, 2019 In Events

InCarda at Biotech Showcase 2019

January 8, 2019 - San Francisco, CA At 2019’s Biotech Showcase conference in San Francisco, InCarda’s Dr. Grace Colón was a guest panelist at the “Early Seed Alternative Financing” Workshop. In that discussion about early company financing, Dr. Colón advised attendees to talk with as many...

November 8, 2018 In Press Releases

InCarda Therapeutics Provides Corporate Update Highlighting Fundraising and Clinical Development Milestones

Oversubscribed $42 Million Series B Financing Provides Significant Runway to Support Continued Advancement of Innovative Inhaled Cardiovascular Therapy First Patients Dosed in Phase 2 Clinical Trial of First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation San Francisco, CA – November 8, 2018 – InCarda Therapeutics, Inc....